Compare i-80 Gold Corp. Common Shares (IAUX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
i-80 Gold Corp. Common Shares vs Pfizer Inc — how do they compare? i-80 Gold Corp. Common Shares trades at $1.49 (market cap $1.26B), while Pfizer Inc trades at $29.49 (market cap $161.70B). The key difference: Pfizer Inc is far larger — about 128.3× i-80 Gold Corp. Common Shares's market cap, and Pfizer Inc pays a 6.06% dividend while i-80 Gold Corp. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold i-80 Gold Corp. Common Shares for 0 Days and Pfizer Inc for 158 Days on average.
| IAUX | PFE | |
|---|---|---|
Market Cap | $1.26B | $161.70B |
Volume | 10,665,602 | 26,828,084 |
Sector | Basic Materials | Health |
52-Week High | $2.08 | $29.21 |
52-Week Low | $0.89 | $23.67 |
Typical Hold Time | 0 Days | 158 Days |
Enterprise Value | $1.24B | $213.20B |
Dividend Yield | — | 6.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAUX trades at $1.54, down 2.53% today, with a neutral technical signal. The company shows significant financial challenges with a -198.82% net income margin and negative ROE of -71.66%, though revenue grew from $95M in 2025 to $130M in 2026. Recent positive developments include CEO purchasing 1 million shares and feasibility studies showing strong potential for Nevada gold projects. Analyst consensus remains unanimously bullish with 3 buy ratings.
While facing substantial profitability challenges, IAUX's development pipeline and CEO confidence suggest long-term potential. Key risks include persistent negative cash flow from operations and high debt levels. The stock presents a high-risk, high-reward opportunity dependent on successful project execution and gold price stability.
Pfizer (PFE) trades at $28.37, down slightly by 0.11% on the day, with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on obesity and oncology pipeline developments, positioning for a catalyst-rich 2026.
Pfizer presents a mixed outlook with stable revenue around $63B but declining net income projections for 2026. The stock trades near analyst consensus target of $29.17, offering modest upside potential. Key risks include patent cliffs and competitive pressures, while the dividend yield and pipeline progress provide defensive appeal for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About i-80 Gold Corp. Common Shares
i-80 Gold Corp. is a mining company focused on developing and operating gold and precious-metals projects in Nevada, using a hub-and-spoke model centered on a processing facility to support multiple mine sites in the state.
Read more on IAUX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
